We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

67 hedge funds and large institutions have $113M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $4.1M | Put options by funds: $680K

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

5% more funds holding

Funds holding: 6467 (+3)

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

58% less capital invested

Capital invested by funds: $268M → $113M (-$154M)

100% less funds holding in top 10

Funds holding in top 10: 50 (-5)

Holders
67
Holders Change
+3
Holders Change %
+4.69%
% of All Funds
1.67%
Holding in Top 10
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
19
Reduced
21
Closed
11
Calls
$4.1M
Puts
$680K
Net Calls
+$3.42M
Net Calls Change
+$2.07M
Name Holding Trade Value Shares
Change
Change in
Stake
GPP
1
Great Point Partners
Connecticut
$18.2M +$6.56M +681,708 +23%
BBA
2
Baker Bros. Advisors
New York
$12.2M
RCM
3
RA Capital Management
Massachusetts
$9.01M
Franklin Resources
4
Franklin Resources
California
$7.42M -$389K -40,400 -3%
PA
5
Perceptive Advisors
New York
$6.55M
DA
6
DSC Advisors
Illinois
$5.87M -$3.59M -373,346 -24%
TCM
7
Tekla Capital Management
Massachusetts
$4.61M
VC
8
Vivo Capital
California
$4.23M
Axa
9
Axa
France
$4.09M +$1.29M +133,602 +19%
DM
10
Deerfield Management
New York
$4.05M -$4M -415,409 -34%
SAM
11
Senzar Asset Management
New York
$2.85M +$229K +23,800 +4%
O
12
OppenheimerFunds
New York
$2.71M -$1.49M -155,129 -22%
BlackRock
13
BlackRock
New York
$2.56M +$4.97M +516,145 New
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$2.49M -$1.46M -151,262 -23%
OM
15
Opaleye Management
Massachusetts
$2.48M +$48.1K +5,000 +1%
FHAM
16
Folger Hill Asset Management
New York
$2.24M +$599K +62,283 +16%
MWNA
17
Marshall Wace North America
New York
$2.22M +$4.27M +443,469 New
DCM
18
Driehaus Capital Management
Illinois
$2.14M -$3.52M -366,193 -46%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.95M -$1.23M -127,482 -24%
Jennison Associates
20
Jennison Associates
New York
$1.68M +$3.27M +340,289 New
DCM
21
DAFNA Capital Management
California
$1.61M +$554K +57,600 +21%
Millennium Management
22
Millennium Management
New York
$1.25M -$250K -26,007 -9%
SFM
23
Sphera Funds Management
Israel
$1.2M -$962K -100,000 -29%
Baillie Gifford & Co
24
Baillie Gifford & Co
United Kingdom
$1.09M
EU
25
Emory University
Georgia
$1.01M +$1.96M +203,519 New

FOMX Hedge Fund Activity: Q1 2017 in Review

67 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2017, worth a combined $113M — down 58% from $268M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new FOMX positions and 11 closed out — a net gain of 4 holders — while 19 added to existing stakes and 21 trimmed.

The largest buyer was Great Point Partners, adding an estimated $6.56M. The largest seller was Menora Mivtachim Holdings, cutting an estimated $12M.

  • 67 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2017, up from 64 in Q4 2016.
  • Funds reported $113M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2017, down 58% quarter-over-quarter.
  • 15 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2017 and 11 closed out, a net change of +4 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q1 2017 was Great Point Partners, an estimated $6.56M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2017 was Menora Mivtachim Holdings, an estimated $12M sold.

Based on aggregated 13F filings for Q1 2017.